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Cannabinoids have been suggested as a therapeutic target for a variety of brain disorders. Despite the
presence of their receptors throughout the auditory system, little is known about how cannabinoids
affect auditory function. We sought to determine whether administration of arachidonyl-20-chlor-
oethylamide (ACEA), a highly-selective CB1 agonist, could attenuate a variety of auditory effects caused
by prior administration of salicylate, and potentially treat tinnitus. We recorded cortical resting-state
activity, auditory-evoked cortical activity and auditory brainstem responses (ABRs), from chronically-
implanted awake guinea pigs, before and after salicylate þ ACEA. Salicylate-induced reductions in
click-evoked ABR amplitudes were smaller in the presence of ACEA, suggesting that the ototoxic effects
of salicylate were less severe. ACEA also abolished salicylate-induced changes in cortical alpha band (6
e10 Hz) oscillatory activity. However, salicylate-induced increases in cortical evoked activity (suggestive
of the presence of hyperacusis) were still present with salicylate þ ACEA. ACEA administered alone did
not induce signiﬁcant changes in either ABR amplitudes or oscillatory activity, but did increase cortical
evoked potentials. Furthermore, in two separate groups of non-implanted animals, we found no evidence
that ACEA could reverse behavioural identiﬁcation of salicylate- or noise-induced tinnitus. Together,
these data suggest that while ACEA may be potentially otoprotective, selective CB1 agonists are not
effective in diminishing the presence of tinnitus or hyperacusis.
© 2017 Published by Elsevier B.V.1. Introduction
Cannabis has been used for centuries, both recreationally and
for medicinal purposes (Kuddus et al., 2013). In the brain, endog-
enous cannabinoids are released postsynaptically and act in a
retrograde manner on presynaptic cannabinoid receptors, sup-
pressing further release of neurotransmitters (Ohno-Shosaku et al.,
2001; Wilson and Nicoll, 2001). There are two types of
presynaptically-located cannabinoid receptors, CB1 and CB2. CB1
receptors are predominantly found in the central nervous system,
whereas CB2 receptors are mainly located on immune cells (see
Pertwee, 2006 for a review), although there are also CB2 receptorsResearch, Science Road, Uni-
Berger).
et al., Effects of the cannabino
ps://doi.org/10.1016/j.heares.located in the rat cochlear nucleus that could have a functional role
(Baek et al., 2008). In the auditory system, CB1 receptors are present
in the spiral ganglion (Stincic and Hyson, 2011), dorsal and ventral
cochlear nucleus (Mailleux and Vanderhaeghen, 1992; Zheng et al.,
2007; Zhao et al., 2009), medial nucleus of the trapezoid body
(Kushmerick et al., 2004), the inferior colliculus (Moldrich and
Wenger, 2000) and the auditory cortex (Eggan and Lewis, 2007).
Their presence throughout the auditory system suggests that they
play a major role in synaptic regulation (Gerdeman and Lovinger,
2001; Medeiros et al., 2016). However, there are relatively few
studies examining how activation of cannabinoid receptors affect
the function of the auditory system.We sought to examinewhether
a highly-selective CB1 agonist could be a potential candidate target
for attenuating auditory effects caused by sodium salicylate.
Sodium salicylate, the primary metabolite of aspirin in the body
(Proost et al., 1983), is commonly used experimentally in animals,
as it is known to cause a variety of auditory effects, includingid CB1 agonist ACEA on salicylate ototoxicity, hyperacusis and tinnitus
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1973; Mcfadden et al., 1984; Day et al., 1989; Cazals, 2000; Zhang
et al., 2014). Ototoxic effects of salicylate are evident in (1)
reduced distortion product otoacoustic emissions (DPOAEs) (Wier
et al., 1988; Stolzberg et al., 2011), indicative of reduced outer
hair cell activity; 2) a reduction in wave I auditory brainstem re-
sponses (ABRs; Berger et al., 2017), indicative of reduced spiral
ganglion activity; and 3) reduced amplitude of cochlear compound
action potentials (Muller et al., 2003; Stolzberg et al., 2011), indic-
ative of reduced cochlear sensitivity, particularly at high fre-
quencies. Contrastingly, cortical evoked responses are enhanced
following salicylate administration (Yang et al., 2007; Sun et al.,
2009; Norena et al., 2010; Berger et al., 2017), suggestive of a
neural correlate of hyperacusis. Furthermore, reductions in alpha
band activity are evident in the auditory cortex of animals following
salicylate administration (Stolzberg et al., 2013; Berger et al., 2017),
which have been suggested as a correlate of reduced inhibition
related to the presence of tinnitus in humans (Weisz et al., 2005;
Lorenz et al., 2009).
While there may be differences in the mechanisms underlying
the effects of salicylate and noise exposure, which is the primary
cause of these conditions in humans, salicylate is particularly useful
as it reliably induces tinnitus, hyperacusis and hearing loss in ani-
mals when administered at a high dose (e.g. Jastreboff et al., 1988;
Lobarinas et al., 2006; Berger et al., 2013, 2017), as opposed to the
variability observed following noise exposure. Furthermore, these
effects are rapid, evident within 2 h in an animal model (Stolzberg
et al., 2011; Berger et al., 2017). It is therefore a useful tool to enable
researchers to more easily test whether particular drugs are
effective in attenuating neural effects relating to these conditions.
Zheng et al. (2007) demonstrated a signiﬁcant reduction in the
number of ventral cochlear nucleus neurons with CB1 receptor
expression following salicylate administration in rats. However,
Zheng et al. (2010) found that CB1 agonists, WIN55,212-2 and CP-
55940, were ineffective in eliminating salicylate-induced behav-
ioural deﬁcits, as identiﬁed using a conditioned suppression task,
and actually induced tinnitus-like behaviour in control rats. In a
follow-up study, Zheng et al. (2015) found that a 1:1 ratio of delta-
9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administered
following noise exposure resulted in a higher number of rats
exhibiting tinnitus-like behaviour. However, these cannabinoid
agonists are not very selective and may also interact with opioid,
vanilloid or muscarinic receptors and this makes the interpretation
of their effects more difﬁcult (Pertwee et al., 2010). These are the
only two animal studies to date examining the effects of cannabi-
noid agonists on tinnitus and further work is required to fully un-
derstand these effects (Smith and Zheng, 2016), including the use of
more selective agonists.
ACEA is a potent, selective full agonist at the CB1 receptor and is
highly speciﬁc, with a 2000-fold higher afﬁnity for the CB1 than the
CB2 receptor. It is a chemically-modiﬁed form of the brain-derived
cannabinoid anandamide and may be metabolised in a similar way
(Hillard et al., 1999). Anandamide is less potent than ACEA and less
efﬁcacious (a partial agonist) while another major endocannabi-
noid in the brain (2-arachidonoyl glycerol) is more efﬁcacious (a full
agonist) but less potent. A number of other synthetic cannabinoids
were available with high potency and high efﬁcacy, but generally
are a lot less selective than ACEA (Pertwee et al., 2010). The phys-
iological effects of CB1 agonists have not been studied in the
auditory forebrain but a recent study by Toal et al. (2016) demon-
strated that CB1 receptor knockout mice had deﬁcits in their au-
diograms above 8 kHz. This suggests a role for CB1 receptors in
regulating normal hearing, despite their inability to diminish
behavioural evidence of tinnitus, and there is a need to further
understand the functional signiﬁcance of the endocannabinoidPlease cite this article in press as: Berger, J.I., et al., Effects of the cannabino
in guinea pigs, Hearing Research (2017), https://doi.org/10.1016/j.heares.system in the auditory system (Smith and Zheng, 2016).
We previously demonstrated that salicylate administration
signiﬁcantly reduced wave I ABR amplitudes, increased cortical
evoked potentials (EPs) and decreased oscillatory alpha band ac-
tivity in auditory cortex (Berger et al., 2017). We therefore sought to
determine whether these neural changes could be attenuated by
ACEA following administration of salicylate in chronically-
implanted awake guinea pigs (GPs). We also examined the effects
of administering ACEA alone on wave I auditory brainstem ampli-
tudes, cortical evoked potentials and spontaneous oscillatory ac-
tivity. In a separate group, we assessed whether ACEA could
successfully prevent the observation of behavioural evidence of
salicylate-induced tinnitus, as assessed using the Preyer reﬂex gap
detection paradigm (Berger et al., 2013). Finally, we examined the
effects of ACEA on noise-induced tinnitus-like behaviour in GPs.2. Materials and methods
2.1. Animals
All procedures were carried out in accordance with the Euro-
pean Communities Council Directive of 24 November 1986 (86/609/
EEC) and the approval of the Animal Welfare and Ethical Review
Body at the University of Nottingham, UK. Electrocorticographic
(ECoG) recordings were made from a total of 6 male and 3 female
tricolour GPs, weighing 500e800 g at the time of implantation
(~2e4 months old). An additional 2 male and 10 female GPs were
used for behavioural testing only and were not implanted. Oestrous
cycles were not accounted for in female GPs, owing to the fact that,
unlike other mammals, they are not easily identiﬁed by visual ex-
amination in this species when single-sex housed (Stockard and
Papanicolaou, 1917). Overall gender and age distributions in the
current study were similar to our previous study (Berger et al.,
2017).2.2. Electrocorticography (ECoG) array implantation
ECoG arrays were prepared and implanted in the same way as
described in Berger et al. (2017). Brieﬂy, 8 uninsulated silver wires
with silver ball ends were soldered onto a circuit board attached to
a Tucker Davis Technologies (TDT: Alachua, FL, USA) zero insertion
force (ZIF)-clip connector. Guinea pigs were initially anaesthetised
with ketamine (40mg/kg, i.p.) and xylazine (8 mg/kg, i.p.), and then
artiﬁcially respired on an isoﬂurane/O2 mixture during the pro-
cedure tomaintain a constant state of areﬂexia. Following amidline
incision and clearing of muscle and connective tissue, electrodes
were placed through burr holes over the rostral and caudal auditory
cortex (AC) on each side, with two more positioned over the cer-
ebellum to record ABRs (see Fig. 1). Reference and ground elec-
trodes were linked via a jumper on the electrode board and
implanted ~3 mm rostral to bregma, just off the midline on either
side. The rostral and caudal electrodes were putatively placed over
the dorsorostral edge of primary AC (abbreviated to rostral) and the
dorsocaudal area (abbreviated to caudal), respectively (Grimsley
et al., 2012).
After electrode insertion, burr holes and the underside of the
electrode board were covered with Kwik-Cast silicone sealant
(World Precision Instruments: Hitchin, UK) and dental acrylic. The
wound was sutured with Mersilk (Ethicon: Livingston, UK) and
covered in antibiotic cream. Cyanoacrylate was applied as an ad-
hesive to the wound around the board. GPs were left for at least
24 h following surgery before baseline ECoG recording.id CB1 agonist ACEA on salicylate ototoxicity, hyperacusis and tinnitus
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Fig. 1. Diagram showing a connector board in relation to a guinea pig skull. The
electrode wires and burr holes are shown diagrammatically with the two most rostral
holes for the ground and reference (red and blue) and the holes for the two most
caudal holes over the cerebellum (green circles at rear). The cortical burr holes (green
lateral circles) and are shown in relation to a diagram of the auditory cortical areas
which have been superimposed on the side of the skull. The rostral cortical electrode
was placed over the dorsorostral belt at the low frequency edge of the primary
auditory cortex (AI). The caudal cortical electrode was placed over the caudal belt at
the low-frequency edge of the dorsocaudal core area. Electrodes were positioned in
relation to local landmarks on the skull, as the lateral suture that forms the border
between the parietal and squamous temporal bones runs obliquely across the middle
of AI, just before turning medially to become the coronal suture. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web version
of this article.)
J.I. Berger et al. / Hearing Research xxx (2017) 1e12 32.3. Recording setup
The ECoG recording setup has been described in detail else-
where (Berger et al., 2017). Brieﬂy, chronic ABR and ECoG re-
cordings were performed inside a sound-attenuated chamber,
using a ZIF-clip digital headstage attached to the GP's implanted
electrode. Auditory stimuli were presented free-ﬁeld via a single
¾-inch tweeter (Tymphany XT19TD00) positioned ~30 cm above
the centre of the cage and were calibrated with two ¼-inch free-
ﬁeld microphones (G.R.A.S. 26AC) placed at either end of the cage
prior to each recording session. Recorded ECoG signals were
ﬁltered online between 0.5 and 300 Hz for resting state oscillatory
activity, 100e5000 Hz for ABRs and 60e300 Hz for EP stimuli. All
data were analysed ofﬂine with custom-written Matlab (R2014b,
MathWorks, MA, USA) scripts. Online data collectionwas facilitated
by either Brainware (software developed by J. Schnupp, University
of Oxford, UK) or custom-written Matlab scripts, depending on the
types of responses being recorded. Data from electrodes that
developed faults were not included in analysis. All experimental
conditions (e.g. GP colony, researchers, stimuli, salicylate dose)
were the same at those employed in Berger et al. (2017).
2.4. ABR stimuli and recording
ABRs were recorded from cerebellar electrodes using custom-
written Matlab scripts. Pure tones between 5 and 20 kHz (70 dB
SPL, 5 ms duration, 0.1 ms on/off ramp) were presented with 500
repeats in a randomised order, and stimulus polarity was alternated
to allow cancellation of stimulus artefact. Ofﬂine, recordings with
an RMS amplitude >3 absolute deviations above the median were
rejected and the remaining data were averaged across repeats.
Median absolute deviation was utilised as it has been shown to
provide a more robust measure of dispersion than standard devi-
ation when detecting outliers (Leys et al., 2013). Peak-to-trough
amplitudes of the largest ABR response (which related to wave I
of the subcutaneously-recorded ABR; see Berger et al., 2017) were
quantiﬁed for each drug treatment and compared to their baselinePlease cite this article in press as: Berger, J.I., et al., Effects of the cannabino
in guinea pigs, Hearing Research (2017), https://doi.org/10.1016/j.heares.values. Data from all animals were pooled and treatment effects
were assessed statistically with a two-way repeated measures
ANOVA and Bonferroni post-hoc test. Data were also assessed as
changes in ABR amplitude (after treatment values/baseline values)
and compared between treatment groups, as well as to the results
of Berger et al. (2017). Unpaired t-tests were used for determining
statistical signiﬁcance between changes in ABR amplitudes for the
different treatment groups (these were assessed as being normally-
distributed with the Shapiro-Wilk normality test), and were only
applied at the frequency in Berger et al. (2017) wherewe observed a
signiﬁcant deﬁcit (20 kHz), in order to examine each group inde-
pendently of one another.
2.5. Oscillations and click-evoked responses
Resting state oscillatory activity and click-evoked responses were
recorded before and after each drug treatment. Data from all baseline
sessions were averaged, consisting of 100 repeats for each session.
For resting state activity, each repeat constituted 10 s of recording in
silence. Data with an RMS >3 absolute deviations above the median
were rejected due to movement artefacts. Power spectral analysis
was performed on every 0.5 s sample of this cleaned dataset,
resulting in an effective spectral smoothing of 2 Hz, and values were
log-transformed in order to express power in decibels (dB) for each
frequency. Analysis was completed ofﬂine using custom-written
Matlab scripts. Statistical analysis comparing baseline resting state
activity with that recorded following each drug treatment was per-
formed using a cluster-based permutation test (Maris and
Oostenveld, 2007). This involved performing two-tailed, one sam-
ple t-tests for each frequency. Frequencies with t-values greater than
a pre-designated threshold (p < 0.05) were clustered based on
spectral adjacency. All t-values within each of these clusters were
summed to produce a cluster-level statistic and the maximum
summed cluster was used as the test statistic. Datawere randomised
across conditions for each GP and this method was repeated for
every possible permutation of the data, creating a distribution of
maximum cluster t-values. The actual data were then referenced to
this distribution, and clusters which fell outside the 95% conﬁdence
interval of the distribution were considered signiﬁcant.
Neural activity was also recorded in response to short clicks
(50 ms), with signals attenuated between 0 and 40 dB SPL of full
output (~100 dB SPL), in 10 dB steps, with an interstimulus interval
(ISI) of 1500 ms. Comparisons between baseline and drug treat-
ment data were made using peak-to-trough amplitudes measured
within 50 ms following the stimulus.
2.6. Drug treatment
Following baseline data collection, we administered intraperi-
toneal injections of either (1) sodium salicylate (350 mg/kg) 2 h
before repeating the above recordings, with ACEA administered
20 min before these recordings (“salicylate þ ACEA”, 1 mg/kg, pre-
dissolved in anhydrous ethanol at 5 mg/ml; n ¼ 5; Tocris, Bristol,
UK), or (2) ACEA alone administered 20 min before neural re-
cordings (“ACEA-only”, 1 mg/kg; n ¼ 4). ACEA was prepared as a
mixture with PEG-35 castor oil (Cremophor EL) and saline solution
(0.9% NaCl) at a ratio of 1:1:18 and left to mix for at least 10 min in
an ultrasonic bath. Salicylate was injected 2 h before neural re-
cordings, as we have previously demonstrated behavioural effects
of salicylate treatment after this time (Berger et al., 2013, 2017).
ACEAwas administered 20min before recordings in both groups, to
ensure that we captured the peak effect of the ACEA whilst re-
cordings were ongoing, as ACEA has been shown to act quickly
following a systemic injection (within 3 min; Hillard et al., 1999)
and peak ~30 min after administration (Hillard et al., 1999;id CB1 agonist ACEA on salicylate ototoxicity, hyperacusis and tinnitus
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J.I. Berger et al. / Hearing Research xxx (2017) 1e124Potenzieri et al., 2008; Reich et al., 2013). Furthermore, at the time
we administered ACEA, we would have expected salicylate to
already have neural effects (Zhang et al., 2011), so we could
examine whether such effects were reversed by ACEA. ACEA was
administered at a dose of 1 mg/kg; this dosage has been shown to
be effective in treating other conditions, such as motor activity
following ischemic stroke (Caltana et al., 2015), while minimising
the in vivo tetrad of side-effects caused by CB1 agonist adminis-
tration (e.g. Crawley et al., 1993).
2.7. Behavioural testing and noise exposure
To determine whether behavioural evidence of tinnitus could
successfully be prevented or reversed by administration of ACEA,
we performed experiments in two separate groups of non-Fig. 2. Mean peak-to-trough amplitudes of ABRs, recorded from cerebellar electrodes, for ea
for left (A; n ¼ 3) and right (B; n ¼ 4) ears, as well as baseline and ACEA-only for left (C; n ¼ 3
as after treatment/before treatment ratios, whereby a ratio of 1 indicates no difference in AB
after treatment. Maroon bars are data from Berger et al. (2017), wherein salicylate was adm
reductions observed previously. Error bars indicate SEM. *p < 0.05; **p < 0.01. G and H: G
salicylate þ ACEA (H). These consist of the means across GPs (averaged across repeats) in
increases in latencies were not as clear. (For interpretation of the references to colour in th
Please cite this article in press as: Berger, J.I., et al., Effects of the cannabino
in guinea pigs, Hearing Research (2017), https://doi.org/10.1016/j.heares.implanted GPs. These GPs were only used in the behavioural task
and no ECoG recordings were performed. The behavioural task
employed was the gap detection paradigm originally devised by
Turner et al. (2006), adapted for use with the pinna reﬂex in GPs
(Berger et al., 2013), whereby a gap in a continuous background
signal preceding a startling stimulus can inhibit the subsequent
startle response, resulting in a reduced magnitude of the startle
reﬂex compared with when no gap is present. Following in-
terventions that cause tinnitus, the effect of the gap-induced in-
hibition is impaired. This is often interpreted as evidence of
tinnitus, although it should be noted that others have suggested
that the test may instead reﬂect temporal coding deﬁcits (see
Galazyuk and Hebert, 2015 for a review).
In the ﬁrst group (n¼ 3), we recorded gap detection behavioural
responses to broadband noise (BBN) stimuli across six trials per GP,ch of the ﬁve frequencies recorded. Data are shown for baseline and salicylate þ ACEA
) and right (D; n ¼ 4) ears. Change in amplitudes are shown for left (E) and right (F) ears
R amplitude (dotted line) and a lower ratio highlights a greater reduction in amplitude
inistered without ACEA. Co-administration of ACEA attenuated the salicylate-induced
rand averaged ABR waveforms, using data from Berger et al. (2017; G) compared to
response to 20 kHz. ACEA attenuated the wave I reductions caused by salicylate, and
is ﬁgure legend, the reader is referred to the web version of this article.)
id CB1 agonist ACEA on salicylate ototoxicity, hyperacusis and tinnitus
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J.I. Berger et al. / Hearing Research xxx (2017) 1e12 5before and 2 h following sodium salicylate administration (350 mg/
kg; i.p.). BBN stimuli were selected as we have previously seen
reliable gap detection deﬁcits with this background carrier
following the same dose of salicylate and at the same time point
(Berger et al., 2013, 2017). Furthermore, focussing on one back-
ground frequency meant that our data yield and statistical power
was much greater than previously, resulting in n ¼ 18 gap-induced
prepulse inhibition (gap-PPI) trials from 3 GPs at each time point.
Sound levels of the background carrier (55, 60, or 70 dB SPL) and
startling stimuli (95, 100, or 105 dB SPL) were determined prior to
baseline recording with a sound level-dependency test (SLDT; see
Berger et al., 2017). Brieﬂy, this involved presenting all different
sound level combinations and assessing which combination pro-
duced the best level of gap-PPI for each GP, along with a reliable
startle response e the optimal levels were then used in baseline
and post-treatment trials. Gap duration (50ms) and number of gap/
no gap presentations (10 of each per trial) were identical to regular
trials, and each trial lasted ~2 min. This procedure was performed
on a separate day prior to baseline data collection.
ACEA was co-administered 20 min before post-salicylate
behavioural testing at the same dose as that used in the ECoG
GPs (1 mg/kg; i.p.), with the hypothesis that if ACEA was successful
in attenuating neural changes underlying tinnitus, there would beFig. 3. Click-evoked potentials. A and B: Mean responses across GPs (±SEM; n ¼ 5) from r
treatment (green). Shading indicates SEM. C and D: Mean responses across GPs (±SEM; n ¼
with ACEA alone (black). (For interpretation of the references to colour in this ﬁgure legen
Please cite this article in press as: Berger, J.I., et al., Effects of the cannabino
in guinea pigs, Hearing Research (2017), https://doi.org/10.1016/j.heares.no signiﬁcant difference between gap/no gap startle ratios before
vs after salicylateþ ACEA treatmente that is, a gap detection deﬁcit
consistent with the presence of tinnitus would not be evident.
Behavioural gap detection data across GPs were grouped and sta-
tistical signiﬁcance was assessed using a Wilcoxon matched-pairs
signed rank test with an alpha of p < 0.05.
In the second group (n ¼ 9), we assessed whether ACEA could
successfully reverse behavioural evidence of noise-induced
tinnitus. Baseline behavioural data were collected for ﬁve
different background carrier frequencies (BBN, 4e6 kHz, 8e10 kHz,
12e14 kHz, 16e18 kHz), as we have previously found gap detection
deﬁcits at a variety of frequencies following the same noise expo-
sure, unlike the uniformity of deﬁcits with salicylate (Coomber
et al., 2014). Behavioural sound levels (background: 55, 60 or
70 dB SPL; startling stimulus: 95, 100 or 105 dB SPL) were selected
with an SLDT (see above). Each trial consisted of 10 startling stimuli
with a gap preceding and 10 startling stimuli with no gap
preceding.
Noise exposure was performed in a similar manner as described
in Coomber et al. (2014) and Berger et al. (2014). Brieﬂy, GPs were
anaesthetised with ketamine (50 mg/kg, i.p.; Fort Dodge Animal
Health Ltd, Southampton, UK) and xylazine (10 mg/kg, i.p.; Bayer
PLC, Newbury, UK), supplementedwith further administrations of aostral AC and caudal AC, recorded during baseline (blue) and after salicylate þ ACEA
4) from rostral AC and caudal AC, recorded during baseline (blue) and after treatment
d, the reader is referred to the web version of this article.)
id CB1 agonist ACEA on salicylate ototoxicity, hyperacusis and tinnitus
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throughout the procedure. Core body temperature was monitored
throughout and maintained at 38 ± 0.5 C using a homeothermic
heating pad (Harvard Apparatus Ltd, Edenbridge, UK) and a rectal
probe. Polyethylene tubes (diameter 20mm)were connected to 25-
mm loudspeakers (Peerless DX25). The right one was disconnected
and plugged with cottonwool, and placed over the folded right ear,
in order to prevent auditory deﬁcits in the right ear. The left speaker
was calibrated using a 40BP 0.25-inch pressure condenser micro-
phone, 26AC preampliﬁer and 12AR power supply (all G.R.A.S,
Holte, Denmark) attached to a calibrated 1-mm-diameter probe
positioned near the entrance to the ear canal. GPs were placed
inside a sound-proof booth and remained there for the duration of
the acoustic trauma. The left ear was exposed to narrow band-
passed noise bursts (duration of 500 ms and ISI of 200 ms; centre
frequency 10 kHz; bandwidth 1 kHz), presented at 116 dB SPL, for
1 h.
Behavioural testing was performed between 7 and 8 weeks
following noise exposure in order to determine whether tinnitus
was present. Each GP was assessed for tinnitus-like behaviour
individually, by comparing sessions recorded after noise exposure
with sessions recorded before noise exposure. Tinnitus frequencies
were identiﬁed using a two-way ANOVA with Bonferroni post-hocFig. 4. Mean peak-to-trough amplitudes of click-evoked responses across GPs (±SEM) for all
and D), caudal AC (B and E) and ABRs (C and F). *p < 0.05; **p < 0.01; ***p < 0.0001.
Please cite this article in press as: Berger, J.I., et al., Effects of the cannabino
in guinea pigs, Hearing Research (2017), https://doi.org/10.1016/j.heares.correction (data were normally distributed, as assessed with the
Shapiro-Wilk normality test). Average behavioural gap/no gap ra-
tios, at frequencies where a signiﬁcant deﬁcit was present, were
compared to baseline values at the same frequencies, in order to
determine the degree of change in behavioural response at the
purported tinnitus frequency/frequencies (calculated by dividing
the mean of baseline gap/no gap ratios by the mean of post-noise
exposure ratios).
GPs were then tested on a further ﬁve separate occasions 20min
after administering ACEA (1 mg/kg; i.p). Two GPs with gap detec-
tion deﬁcits were reserved for administering ACEA vehicle-only
20 min before behavioural recording. ACEA vehicle was prepared
and administered using the same ratio as described earlier for
ACEA, but with ethanol substituted for ACEA. The worst session
from each time point (baseline, 7e8 weeks and ‘treatment’) was
discarded prior to analysis to prevent skewing of the data, for
example, on days when GPs were particularly active. Average gap/
no gap ratios for the tinnitus frequency/frequencies following
treatment were compared to baseline values and Wilcoxon signed
rank tests were used to compare changes in gap/no gap ratios
across GPs after treatment vs 7e8 weeks, in order to determine
whether ACEA or vehicle administration could signiﬁcantly affect
behavioural evidence of noise-induced tinnitus.attenuations recorded during baseline and after drug administration from rostral AC (A
id CB1 agonist ACEA on salicylate ototoxicity, hyperacusis and tinnitus
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3.1. ABR wave I amplitudes
Suprathreshold (70 dB SPL) ABRs were recorded before and 2 h
after salicylate administration, as well as 20 min after ACEA
administration, for ﬁve different frequencies: 5 kHz, 7.07 kHz,10 kHz,
14.1 kHz and 20 kHz. Previously, we observed a signiﬁcant decrease
in ABR amplitudes following salicylate administration (without co-
administration of ACEA; Berger et al., 2017). Average ABR wave I
amplitudes for both treatments are shown in Fig. 2. Contrasting with
the results of Berger et al. (2017), when ACEA was co-administered
with salicylate (salicylate þ ACEA group), there was no signiﬁcant
effect of treatment on ABR amplitudes for either the left ear
(F(1,10) ¼ 2.83, p ¼ 0.12) or the right ear (F(1,15) ¼ 3.88, p ¼ 0.07),
although a small reduction in wave I amplitudes was evident at
20 kHz for both ears (Fig. 2A and B), albeit not to a statistically sig-
niﬁcant extent. Furthermore, there was no signiﬁcant effect of
treatment on ABR amplitudes for the left ear (F(1,10) ¼ 3.04, p ¼ 0.11)
or the right ear (F(1,15) ¼ 0.02, p ¼ 0.90) following administration of
ACEA by itself (ACEA-only group), thereby suggesting that ACEA did
not simply increase ABR wave I amplitudes (Fig. 2C and D).
Changes in ABR amplitudes at 20 kHz were also compared
directly with the results of Berger et al. (2017; Fig. 2E and F) and
expressed as a ratio calculated as after treatment amplitude/before
treatment amplitude, whereby a ratio of 1 indicated no difference
in ABR amplitude and lower ratios highlighted a greater reductionFig. 5. Mean resting-state activity power spectra (±SEM), recorded during baseline and follo
and D, rostral; n ¼ 4). Blue lines indicate baseline activity and blue or black lines indicate
signiﬁcant difference. Inset ﬁgures (furthest right) show expanded area where a signiﬁcant
2017). (For interpretation of the references to colour in this ﬁgure legend, the reader is ref
Please cite this article in press as: Berger, J.I., et al., Effects of the cannabino
in guinea pigs, Hearing Research (2017), https://doi.org/10.1016/j.heares.in amplitude, as we previously observed a signiﬁcant deﬁcit at this
frequency following salicylate administration alone. For the left ear,
in the salicylateþ ACEA group, there were some reductions evident
in ABR amplitudes, giving a mean ratio (±SEM) of 0.55 (±0.03), but
this change was signiﬁcantly smaller than what we found previ-
ously when administering salicylate alone (Berger et al., 2017;
maroon bars), t (6) ¼ 4.96, p ¼ 0.003, wherein the mean ratio
(±SEM) was 0.27 (±0.04). For the right ear, this change was again
signiﬁcantly smaller in the salicylate þ ACEA group compared to
the previous data from Berger et al. (2017), t (7) ¼ 2.63, p ¼ 0.03,
with a mean ratio (±SEM) of 0.54 (±0.13) compared with a mean
ratio of 0.20 (±0.05) when salicylate was administered without
ACEA. This attenuation of the salicylate-induced reductions of wave
I amplitudes by ACEA is further emphasised by Fig. 2G and H, which
show left ear grand averages of ABRs in salicylate GPs (from Berger
et al., 2017) compared to salicylate þ ACEA.
ACEA administered alone resulted in a mean change in ABR
ratios at 20 kHz on the left and right of 1.20 (±0.34) and 1.24 (±0.14)
respectively. For the left ear, these were signiﬁcantly higher than
the Berger et al. (2017) ratios, t (6) ¼ 3.70, p ¼ 0.01, but not
signiﬁcantly different than the salicylateþ ACEA ratios, t (4) ¼ 1.93,
p ¼ 0.13. For the right ear, these ratios were signiﬁcantly higher
than both the Berger et al. (2017) ratios, t (7)¼ 7.65, p¼ 0.0001, and
the salicylateþ ACEA ratios, t (6)¼ 3.59, p¼ 0.01. These data further
highlight that, although salicylatewas still affecting ABR sensitivity,
co-administration of ACEA appeared to attenuate the effects of
salicylate on ABR amplitudes at the highest frequency we assessedwing either salicylate þ ACEA (A, caudal and B, rostral; n ¼ 5) or ACEA-only (C, caudal
activity following drug treatment. Magenta shading between lines in (A) highlights
difference was demonstrated previously following salicylate treatment (Berger et al.,
erred to the web version of this article.)
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Fig. 6. A: BBN Behavioural gap detection ratios (gap-PPI) before and after
salicylate þ ACEA administration, averaged across GPs (n ¼ 3 GPs, 18 gap-PPI trials).
There was a signiﬁcant increase in the gap detection ratio of the pinna reﬂex following
co-administration of the two drugs, which highlights that gaps in otherwise contin-
uous background noise were less effective at inhibiting the response following a
startling stimulus, consistent with the presence of tinnitus (*p < 0.05). B:Mean change
from baseline in gap-PPI across GPs (±SEM) following salicylate þ ACEA, compared
with data from Berger et al. (2017) wherein salicylate was administered without ACEA.
A value of 1 would indicate no change in behavioural gap detection ability compared to
baseline, whilst higher values would suggest improvement and lower values wors-
ening. There was no signiﬁcant difference between the two groups.
J.I. Berger et al. / Hearing Research xxx (2017) 1e128(20 kHz).
3.2. ABR wave I latencies
Latencies of the N1 and P1 components of wave I of the ABR
were compared for salicylate þ ACEA and ACEA alone at all ﬁve
frequency bands, as we had previously demonstrated a signiﬁcant
increase in P1 and N1 latencies at 20 kHz following salicylate
administration (Berger et al., 2017), with increases between 0.12
and 0.16 ms. In the salicylate þ ACEA group, there was a general
effect of treatment across GPs, with an increase in P1 latencies for
the left ear (0.04 ms ± 0.01 SEM; F(1,10) ¼ 4.97, p ¼ 0.05) and the
right ear (0.06 ms ± 0.01 SEM; F(1,15) ¼ 16.93, p ¼ 0.0009), although
post-hoc testing revealed that there was not one particular fre-
quency with a signiﬁcant increase in P1 latency. There was also a
general increase in N1 latencies across GPs for the left ear
(0.04 ms ± 0.01 SEM; F(1,10) ¼ 8.65, p ¼ 0.01) and the right ear
(0.07 ms ± 0.02 SEM; F(1,15) ¼ 24.66, p ¼ 0.0002), although the only
particular frequency with a signiﬁcant increase was 20 kHz for the
right ear (t ¼ 3.490, p < 0.05), with a mean increase of 0.11 ms
(±0.03 ms). In the ACEA-only group, there was no signiﬁcant effect
of treatment on N1 latencies for the left ear (F(1,10) ¼ 2.61, p ¼ 0.14)
or the right ear (F(1,15)¼ 2.16, p¼ 0.16), and the samewas true for P1
latencies in both the left ear (F(1,10) ¼ 0.02, p ¼ 0.89) and the right
ear (F(1,15) ¼ 0.01, p ¼ 0.92).
3.3. Click-evoked cortical EPs
Fig. 3 shows EPs in response to 50 ms clicks before vs after the
administration of either salicylate þ ACEA or ACEA alone, averaged
across GPs and recorded with a signal attenuation of 0 dB SPL
(approximately 100 dB SPL RMS), while Fig. 4 shows peak-to-trough
responses for both groups across all sound levels. Salicylate þ ACEA
resulted in increases in click-EPs, similar to what we have observed
previously with salicylate only (Berger et al., 2017), ranging from 61
to 89% for rostral AC and 145e159% for caudal AC (Fig. 4A and B). All
of these increases were signiﬁcant (p < 0.05), with the greatest ef-
fects seen at the loudest sound levels. There were no clear or sig-
niﬁcant changes in cerebellar click-evoked potentials (Fig. 4C). ACEA
alone slightly increased EPs for all electrodes (Fig. 4DeF), although
there was a considerable degree of variability across GPs and the
effect was much lower than that caused by salicylate þ ACEA,
ranging from 34 to 48% for rostral AC, 30e39% for caudal AC and
24e54% for cerebellar electrodes. Nonetheless, these changes were
signiﬁcant for rostral AC and caudal AC at the loudest sound levels
(between 20 and 0 dB attenuation; p< 0.05), but were not signiﬁcant
for cerebellar EPs at any sound level. In summary, these data indicate
that co-administration of ACEA did not attenuate the increases in
click-EPs caused by salicylate, and ACEA alone caused slight increases
in EPs.
3.4. Cortical oscillatory activity
Data recorded in silence from rostral and caudal electrodes were
fast Fourier transformed in order to produce power spectra. Fig. 5
shows mean power spectra averaged across GPs for each group,
collected before and after each treatment. Cluster-based permuta-
tion analyses were applied to determine statistical signiﬁcance
with an alpha level of p < 0.05. In the salicylateþ ACEA group, there
was a signiﬁcant decrease in activity between 22 and 34 Hz on the
rostral electrodes (Fig. 5A). However, co-administration of ACEA
with salicylate did not produce any signiﬁcant changes in oscilla-
tory activity on the caudal electrodes (Fig. 5B). ACEA administered
alone did not cause any signiﬁcant changes on either the rostral
electrodes (Fig. 5C) or the caudal electrodes (Fig. 5D). In summary,Please cite this article in press as: Berger, J.I., et al., Effects of the cannabino
in guinea pigs, Hearing Research (2017), https://doi.org/10.1016/j.heares.the change in oscillatory alpha band activity that we have observed
previously following salicylate treatment (Berger et al., 2017) was
not present when ACEA was co-administered.
3.5. Behavioural responses following salicylate þ ACEA
administration
Fig. 6 shows behavioural responses before and after
salicylateþ ACEA co-administration, plotted as ratios of gap/no gap,
which are indicative of the degree of gap-PPI. Following
salicylateþ ACEA administration, therewas a signiﬁcant increase in
the gap-PPI ratio across GPs (p ¼ 0.026), similar to what we have
seen previously when administering salicylate alone (Berger et al.,
2013, 2017). This indicates that behavioural gap detection ability
was impaired following co-administration of both drugs, which is
suggestive of the presence of tinnitus and demonstrates that ACEA
failed to prevent behavioural identiﬁcation of salicylate-induced
tinnitus. Furthermore, these data were compared directly with
data from Berger et al. (2017), wherein salicylate was administered
without ACEA.When examining the change in gap-PPI as a function
of before salicylate vs after salicylate, calculated for each GP by
dividing gap-PPI ratios before drug administration by gap-PPI ratios
after, the mean change in gap-PPI ratio (before/after) following
salicylate þ ACEA was 0.80 (±0.34 SEM), compared to 0.77 (±0.07
SEM) following salicylate without ACEA (data from Berger et al.,
2017). This difference was not signiﬁcant (U ¼ 6, p ¼ 0.79),
further highlighting that ACEA did not attenuate the behaviouralid CB1 agonist ACEA on salicylate ototoxicity, hyperacusis and tinnitus
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Behavioural testing for evidence of tinnitus 7e8 weeks
following unilateral noise exposure indicated that 7 of the 9 GPs
demonstrated signiﬁcant gap detection deﬁcits at one of more of
the frequencies tested, which is proportionally comparable to what
we have observed previously with a similar noise exposure
(Coomber et al., 2014). In some cases, behavioural gap detection
deﬁcits were observed at more than one background frequency.
There were signiﬁcant deﬁcits at 4e6 kHz in four GPs, 12e14 kHz in
two GPs,16e18 kHz in two GPs and BBN in one GP. Fig. 7A shows an
example of a GPwith a signiﬁcant deﬁcit at 4e6 kHz, expressed as a
change in gap-PPI after noise exposure vs before.
Following behavioural testing for tinnitus, GPs were adminis-
tered either ACEA or ACEA-vehicle on ﬁve separate occasions and
their behavioural responses were recorded. Behavioural responses
at the suggested tinnitus frequency/frequencies were expressed as
an average change in gap-PPI at either the 7e8 week time point or
the treatment time point compared to baseline, and data were
grouped across GPs. The data for these GPs are shown in Fig. 7B.
There was no signiﬁcant difference in the change in gap-PPI at
purported tinnitus frequencies between the 7e8 week time point
and the treatment time point, for either ACEA administrationFig. 7. Change in behavioural gap detection ratios (gap-PPI) 7e8 weeks following noise
exposure and ACEA administration. A: An example of a GP with behavioural evidence
of tinnitus. Gap detection ability was signiﬁcantly worse at the 4e6 kHz background
carrier seven-to-eight weeks following noise exposure, compared to baseline (grey
bar; *p < 0.05). B: Change in gap-PPI at the tinnitus frequency for each time point,
compared to baseline (n ¼ 6 frequencies for ACEA; n ¼ 3 frequencies for vehicle),
averaged across GPs. There were no signiﬁcant changes in behavioural gap detection
deﬁcits following either ACEA administration (green bars) or vehicle treatment
(maroon bars). (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
Please cite this article in press as: Berger, J.I., et al., Effects of the cannabino
in guinea pigs, Hearing Research (2017), https://doi.org/10.1016/j.heares.(p ¼ 0.16; n ¼ 6 frequency bands from 5 GPs) or vehicle adminis-
tration (p ¼ 0.25; n ¼ 3 frequency bands from 2 GPs), thereby
highlighting that ACEA did not signiﬁcantly affect behavioural ev-
idence of noise-induced tinnitus.
4. Discussion
The synthetic cannabinoid agonist, ACEA, attenuated some of
the effects that we previously observed with salicylate adminis-
tration. Namely, it attenuated the reductions in ABR wave I am-
plitudes and the increases in peak latencies, as well as abolishing
decreases in cortical oscillatory activity within the 6e10 Hz band.
However, increases in cortical evoked potentials caused by salicy-
late were not attenuated by co-administration of ACEA. Further-
more, behavioural evidence of both salicylate- and noise-induced
tinnitus was still evident following administration of ACEA, sug-
gesting that highly-selective CB1 agonists do not prevent the
identiﬁcation of tinnitus or reverse the presence of tinnitus.
4.1. Potential otoprotective effects of ACEA
We previously demonstrated that wave I amplitudes were
signiﬁcantly reduced following salicylate administration at 20 kHz
(Berger et al., 2017). Following co-administration of ACEA with
salicylate, although there were still reductions in wave I ampli-
tudes, these effects were diminished and not signiﬁcant, suggesting
that ACEA had attenuated the ototoxic effects of sodium salicylate.
Changes in latencies following salicylate were also attenuated by
co-administration of ACEA. Moreover, ACEA administered alone did
not cause changes in wave I ABR amplitudes.
Salicylate is known to cause reversible ototoxicity
(Stypulkowski, 1990), which may occur through a reduction in
outer hair cell electromobility (e.g. Kakehata and Santos-Sacchi,
1996). This would result in a reduction in cochlea sensitivity,
which could explain the decreases in wave I ABR amplitudes that
we have previously observed. Given that the attenuating effect of
ACEA that we have observed here is purely phenomenological, we
can only speculate as to the underlyingmechanisms. There is recent
evidence that CB1 receptors are present in the cochlea, although the
CB2 receptors appeared more prevalent (Martin-Saldana et al.,
2016). Furthermore in the same study, following cisplatin treat-
ment, which produces ototoxicity, CB1 receptor expression was
downregulated in spiral ganglion neurons. Jeong et al. (2007) also
demonstrated that a CB1 agonist, HU-210, could prevent apoptosis
of hair cells following cisplatin treatment. Recent data suggest that
salicylate may kill spiral ganglion neurons over the course of
several days as a result of enhancing activation of NMDA receptors
(Deng et al., 2013).
Cannabinoids have been shown to prevent neurotoxicity caused
by over-activation of NMDARs in other conditions (e.g. El-Remessy
et al., 2003), as they can act in a similar manner to non-competitive
NMDAR antagonists (Feigenbaum et al., 1989). Therefore, by acti-
vating CB1 receptors it is possible that we attenuated processes that
would lead to the apoptotic effects of salicylate that have previously
been demonstrated (Wei et al., 2010; Feng et al., 2011). All of the
above, combined with the fact that mice missing CB1 receptors
possess poorer hearing thresholds than wild-type mice (Toal et al.,
2016), suggests an important role for CB1 receptors in protecting
and maintaining normal hearing function. Clearly further work is
required in order to determine the speciﬁc underlying mechanisms
by which activation of CB1 receptors may attenuate damage caused
by salicylate.
Furthermore, it would be of interest to determinewhether ACEA
is successful at attenuating damage to the periphery caused by
noise exposure. Given that we did not examine ABRs in our noiseid CB1 agonist ACEA on salicylate ototoxicity, hyperacusis and tinnitus
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determine whether this was the case in our GPs. Recent work by
Zheng et al. (2015) did not ﬁnd a difference in ABR thresholds be-
tween noise-exposed rats administered delta-9-THC andCBD, so
the effects seen here may only be apparent in salicylate-induced
hearing loss. However, absolute ABR thresholds do not appear to
be as sensitive as ABR amplitudes at suprathreshold sound levels in
measuring the extent of damage at the periphery (Kujawa and
Liberman, 2009). It is also possible that administering a CB1
agonist prior to an acoustic insult (as opposed to after) may prevent
subsequent damage, rather than reversing already-induced dam-
age. If this was the case, however, then the impact of such a
treatment would be limited in humans, as it would not reverse pre-
existing damage.
4.2. No effect on cortical evoked potentials
Despite the attenuation of effects observed at the periphery, co-
administration of ACEA failed to attenuate the effects of salicylate
on cortical evoked potentials, and in fact signiﬁcantly increased
click-evoked potentials at the highest sound levels when admin-
istered alone. To our knowledge, this is the ﬁrst demonstration of
effects of a CB1 agonist on auditory cortex EP amplitudes, although
enhancements in EPs have previously been demonstrated in the
hippocampus with the CB1 agonist WIN55,212-2 (Dissanayake
et al., 2008). This also suggests a central mechanism for
salicylate-induced hyperacusis, independent of peripheral activity,
an idea supported by others (Stolzberg et al., 2012b; Chen et al.,
2013; Radziwon et al., 2017). There is clear evidence that salicy-
late administered systemically enters both the cochlear perilymph
and cerebrospinal ﬂuid (Jastreboff et al., 1986), thereby directly
affecting auditory areas of the central nervous system (see
Stolzberg et al., 2012a for a review). Therefore, it is not inconsistent
that we observed different effects on wave I ABR activity to cortical
evoked activity, as both drugs would likely act peripherally and
centrally.
CB1 receptors are present in cholecystokinin-expressing large
basket cells in the neocortex (e.g. Bodor et al., 2005), which are
inhibitory interneurons. In these neurons, CB1 receptors are located
presynaptically, which has a net effect of depressing inhibition (see
Allene et al., 2015 for a review). This is evidenced by the fact that
administration of a CB1 agonist suppresses inhibition in layers 2/3
of the auditory cortex (Trettel and Levine, 2002). Therefore, it is
perhaps not surprising that EP amplitudes were slightly enhanced
by cannabinoids. Consistent with this ﬁnding, Guy and Flint (2004)
reported hyperacusis in humans as an adverse side effect of oral
administration of CBD:THC prepared as a 1:1 ratio.
4.3. Decreases in alpha band oscillations absent following co-
administration of salicylate with ACEA
We previously demonstrated a signiﬁcant reduction in alpha
band activity in caudal AC following salicylate administration
(Berger et al., 2017). Following co-administration of ACEA, signiﬁ-
cant changes in alpha band activity were not present in the current
study. If a reduction in alpha band activity is a neural correlate of
tinnitus, then this would suggest that ACEA was successfully
eliminating the neural underpinnings of tinnitus. However, Zheng
et al. (2010, 2015) found that CB1 agonists were ineffective at
reducing behavioural evidence of tinnitus following either salicy-
late or noise exposure. Furthermore, we found that ACEA was un-
successful in preventing behavioural evidence of salicylate-induced
tinnitus or reversing behavioural evidence of noise-induced
tinnitus, which is consistent with the results of Zheng et al.
(2010, 2015). Therefore, even if a reduction in alpha band activityPlease cite this article in press as: Berger, J.I., et al., Effects of the cannabino
in guinea pigs, Hearing Research (2017), https://doi.org/10.1016/j.heares.is an underlying contributor to the tinnitus percept, given that a
cannabinoid agonist did not abolish behavioural evidence of
tinnitus, but did prevent changes in alpha band activity following
salicylate administration, it appears unlikely that it is necessary for
generating the phantom percept.
One limitation of the current study is that the effect of vehicle
administration on behavioural deﬁcits following noise exposure
was only examined in two guinea pigs (one of which had putative
tinnitus at two background frequencies, resulting in n ¼ 3 tinnitus
frequencies before vs after vehicle). Therefore, although we did not
observe any effect, the statistical test in this case would have likely
been underpowered. However, behavioural deﬁcits following noise
exposure were also unchanged following ACEA administration
(with n ¼ 6 putative tinnitus frequencies), which made the com-
parisonwith vehicle GPs less crucial. As a result, we do not feel that
the low number of vehicle controls signiﬁcantly affects the con-
clusions we can draw from the data.
Signiﬁcant decreases in low gamma activity were evident in
rostral AC following co-administration of salicylate and ACEA. We
demonstrated previously that both a vehicle and a salicylate in-
jection were capable of producing increases in gamma activity in
this same region (Berger et al., 2017), which we suggested may be a
result of stress associated with the injection. The decreases in
gamma we have observed here therefore suggest that the ACEA
injection may actually reduce stress in these GPs. This idea, how-
ever, is not supported by the fact that we did not see any signiﬁcant
changes following an injection of ACEA alone. Therefore, there
could be an interaction effect between salicylate and ACEA that
results in this change in low gamma activity.
Whilst we did not observe such a reduction in gamma band
activity with administration of ACEA only, previous studies have
demonstrated that another CB1 agonist, CP-55940, reduced gamma
oscillations in other areas, including in the hippocampus and en-
torhinal cortex (Robbe et al., 2006; Hajos et al., 2008) and prefrontal
cortex (Kucewicz et al., 2011). Conversely, Morgan et al. (2008)
failed to ﬁnd a difference in neural oscillations in the medial en-
torhinal cortex following application of the CB1 agonist arach-
idonylcyclopropylamide (ACPA) in vitro. Nonetheless, clearly
further research is required to properly understand the mecha-
nisms underlying changes in oscillatory activity observed here.
In summary, ACEA appeared to attenuate salicylate-induced
reductions in wave I of the ABR and alpha-band neural oscilla-
tions, but did not attenuate salicylate-induced increases in cortical
evoked potentials or affect tinnitus-like behaviour. This suggests
that ACEA may be potentially otoprotective, and that hyperacusis-
like activity may occur independent of peripheral insult, but CB1
agonists are not suitable as a potential treatment for tinnitus.
Further research is necessary to determine whether ACEA can
effectively attenuate peripheral damage caused by excessive noise
exposure.
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